CANNAPHARMARX, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-11.1M | $-9.9M | $3.7M | $-8.5M | $-8.8M | $-19.9M | $-20.5M | $-3.1M |
| Depreciation & Amortization | — | $0 | $127.8K | $294.9K | $2.7K | $128.5K | $129.0K | $0 |
| Depreciation | — | — | — | $12.8K | $2.7K | $1.5K | $779 | $0 |
| Amortization | — | — | — | — | $0 | $127.0K | $128.3K | $0 |
| Stock-Based Compensation | — | — | — | $181.0K | $363.1K | $820.4K | $736.2K | $27.7K |
| Net Cash from Operating Activities | $-789.1K | $-1.7M | $-2.3M | $-1.4M | $-2.4M | $-563.6K | $-3.8M | $-941.1K |
| Investing Activities | ||||||||
| Capital Expenditures | $5.5K | $0 | $80.6K | $116.0K | $6.3K | $0 | $4.8K | $0 |
| Business Acquisitions | — | — | — | — | — | — | $0 | $726.7K |
| Net Cash from Investing Activities | $794.3K | $1.7M | $-80.6K | $-116.0K | $493.6K | $0 | $-46.9K | $-726.7K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | $0 | $99.0K | $0 |
| Net Cash from Financing Activities | $-5.5K | $0 | $2.4M | $1.4M | $1.3M | $824.6K | $3.3M | $2.1M |
| Net Change in Cash | $-352 | $1.5K | — | $-25.5K | $-307.2K | — | — | — |
| Free Cash Flow | $-794.6K | $-1.7M | $-2.4M | $-1.6M | $-2.4M | $-563.6K | $-3.8M | $-941.1K |